



## CLINIGENE INDUSTRY SATELLITE: *JOINT PLATFORM BETWEEN INDUSTRY & CENTERS OF EXCELLENCE-3<sup>RD</sup> EDITION*

Tuesday November 24<sup>th</sup> 2009 Location:

### GMP manufacture of Gene Therapy Vectors & Genetically modified cells: Present status & future needs

This meeting, open to the public, is aiming at streamlining interaction between the private and the public sectors, an objective which is identified as a CliniGene priority.

**13:30 - 13:45**

**Establishing an ad hoc EU INFRASTRUCTURE**

- **Introduction**  
Odile Cohen-Haguenauer (ENSC, APHP & CliniGene coordinator, Paris-France)

**13:45 - 14:45**

**GMP manufacture: Examples of current developments**

**Chairmen:** Martin Wisher (Bioreliance, Stirling-Scotland) & Manuel Carrondo (IBET, Oeiras-Portugal)

- **Development of safe and efficient non-viral vector systems** 10'+5'  
Martin Schleaf (PlasmidFactory, Bielefeld-Germany)
- **An improved packaging system for gammaretro- and lentiviral bidirectional vectors** 5'+5'  
Tobias Maetzig (MHH, Hannover-Germany)
- **Modified plastic surfaces for adherent cells growth, genetic modification & cell selection** 5'+5'  
Olivier Schön (HZI, Braunschweig-Germany)
- **Process development of SMART-DCs for melanoma immunotherapy clinical trials** 5'+5'  
S. Kuhs\*
- **Baculovirus for GT: use of metabolomics for production & membranes for purification** 10'+5'  
Manuel Carrondo (IBET, Oeiras-Portugal)

**14:45**

**15:30**

**GMP manufacture: Future needs**

**Chairpersons:** Mary Collins (UCL, London-UK)\* & Christof von Kalle (DKFZ, Heidelberg-Germany)\*

- **EU training programme** 5'+5'  
Seppo Ylä-Herttua (University of Kuopio, Kuopio-Finland) & Gösta Gahrton (Karolinska Institut., Stockholm SW)
- **GMP manufacture of AAV vectors: current status & future needs** 10'+5'  
Philippe Moullier (Genethon, Evry-France & EFS-INSERM, Nantes)\*
- **Scalable approach to research grade AAV vector manufacturing** 5'+5'  
Jaan Toelen (Catholic University of Leuven, Leuven-Belgium)
- **Future needs in the GMP manufacture of genetically modified cells** 5'+5'  
Werner Lindenmaier (HZI, Braunschweig-Germany)\*

**15:30 - 16:30**

**ROUND TABLE: Articulation between academic GMP production centres and the private sector & Future needs**

**Chairmen:** Gösta Gahrton (Karolinska Institut., Stockholm SW) & Jacques Demotes (ECRIN Inserm, FR)

**Participants:** Philippe Moullier (Genethon & Nantes)\*, Pontus blomberg (Vecura, KI Stockholm)\*, (Molmed, Milan)\*, Kyri Mitrophanos (OBM, Oxford)\*, Mark Federspiel (Mayo Clinic, Rochester)\*, Martin Wisher (Bioreliance, Stirling), Robert Shaw (Ark-Therapeutics, London?)\*, Carla Paganin (Telethon-Italia, Milan)\*, Harald Petry (AMT, Amsterdam)\*, Monika Lusky (Transgene, Illkirch)\*, Klaus Kuehlcke (EUFETS, Idar-Oberstein)\*.

\* confirmation pending